Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

15.0x

Market Cap

CNY 4.65B

MomentumView details →

1D Return

−0.51%

YTD Return

−12.42%

RSI (14)

48.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

15.0x

Market Cap

CNY 4.65B

RSI (14)

48.0

MomentumView details →

1D Return

−0.51%

YTD Return

−12.42%

ProfitabilityView details →

Gross Margin

36.79%

Net Margin

3.75%

EBITDA Margin

17.26%

ROE (TTM)

1.42%

ROA (TTM)

1.12%

Asset Turnover

0.29x

GrowthView details →

Revenue YoY

−18.13%

EPS YoY

−66.24%

FCF YoY

+623.75%

Revenue CAGR 3Y

−10.46%

EPS CAGR 3Y

−29.33%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.10x

Current Ratio

2.25x

Quick Ratio

1.44x

Div Yield

1.80%

Div Rate

CNY 0.07

Div Growth 1Y

−28.57%

Financials snapshotView financials →

Revenue (TTM)

1.68B

Net Income (TTM)

62.86M

Op. CF (TTM)

369.87M

Latest newsMore news →

Fuan Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 95.7748 million yuan, down 15.33% year-on-year.11d ago

Fu'an Pharmaceutical and its wholly-owned subsidiaries Tianheng Pharmaceutical, Zhichu Pharmaceutical, and Renmin Pharmaceutical participated in the bidding for the 12th national centralized drug procurement on July 31, 2026, with three drugs (Nicardipine Hydrochloride Injection, Teicoplanin for Injection, and Isavuconazole Sulfate for Injection) provisionally selected, with the procurement period running from the effective date of the selection results to December 31, 2029.34d ago

Similar companies

张小泉301055.SZ 万祥科技301180.SZ 卫光生物002880.SZ 南兴股份002757.SZ 天能重工300569.SZ 丰立智能301368.SZ Find similar companies →

Latest newsMore news →

Fuan Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 95.7748 million yuan, down 15.33% year-on-year.11d ago Fu'an Pharmaceutical and its wholly-owned subsidiaries Tianheng Pharmaceutical, Zhichu Pharmaceutical, and Renmin Pharmaceutical participated in the bidding for the 12th national centralized drug procurement on July 31, 2026, with three drugs (Nicardipine Hydrochloride Injection, Teicoplanin for Injection, and Isavuconazole Sulfate for Injection) provisionally selected, with the procurement period running from the effective date of the selection results to December 31, 2029.34d ago